Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small-Cell Lung Cancer after Progression during First-Line EGFR Tyrosine Kinase Inhibitor Therapy

被引：3
|
作者：
Hoyle, Christopher [1 ]
Dyer, Matthew [1 ]
机构：
[1] AstraZeneca, Acad House,136 Hills Rd, Cambridge CB2 8PA, Cambs, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 05期
关键词：
D O I：
10.1016/j.jtho.2018.02.006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E83 / E84
页数：2
相关论文
共 50 条
  • [1] Response: Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR Tyrosine Kinase Inhibitor Therapy
    Wu, Bin
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (05) : E84 - E85
  • [2] Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR TKI Therapy
    Wu, Bin
    Gu, Xiaohua
    Zhang, Qiang
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (02) : 184 - 193
  • [3] COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE OSIMERTINIB IN PATIENTS WITH EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER
    Holleman, M. S.
    Al, M. J.
    Uyl-de Groot, C. A.
    VALUE IN HEALTH, 2018, 21 : S3 - S3
  • [4] Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
    Ramalingam, Suresh S.
    Yang, James C-H
    Lee, Chee Khoon
    Kurata, Takayasu
    Kim, Dong-Wan
    John, Thomas
    Nogami, Naoyuki
    Ohe, Yuichiro
    Mann, Helen
    Rukazenkov, Yuri
    Ghiorghiu, Serban
    Stetson, Daniel
    Markovets, Aleksandra
    Barrett, J. Carl
    Thress, Kenneth S.
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (09) : 841 - +
  • [5] Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China
    Cai, Hongfu
    Zhang, Longfeng
    Li, Na
    Chen, Shen
    Zheng, Bin
    Yang, Jing
    Weng, Lizhu
    Liu, Mao-Bai
    CLINICAL THERAPEUTICS, 2019, 41 (02) : 280 - 290
  • [6] OSIMERTINIB AS FIRST-LINE AND SECOND-LINE THERAPY FOR EGFR MUTATION-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER: A COST-EFFECTIVENESS ANALYSIS IN CHINA
    Zhou, J.
    Jiang, G.
    VALUE IN HEALTH, 2020, 23 : S54 - S54
  • [7] First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis
    Holleman, Marscha S.
    van Tinteren, Harm
    Groen, Harry J. M.
    Al, Maiwenn J.
    Uyl-de Groot, Carin A.
    ONCOTARGETS AND THERAPY, 2019, 12 : 1413 - 1421
  • [8] EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
    Nan, Xueli
    Xie, Chao
    Yu, Xueyan
    Liu, Jie
    ONCOTARGET, 2017, 8 (43) : 75712 - 75726
  • [9] EGFR Tyrosine Kinase Inhibitor and Chemotherapy in EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Nishino, Kazumi
    Kimura, Madoka
    Inoue, Takako
    Uchida, Junji
    Kumagai, Toru
    Imamura, Fumio
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S526 - S526
  • [10] Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada
    Kim, Yong-Jin
    Oremus, Mark
    Chen, Helen H.
    McFarlane, Thomas
    Fearon, Danielle
    Horton, Susan
    PHARMACOECONOMICS, 2021, 39 (05) : 537 - 548
12345